Opportunity Information: Apply for PAR 22 165
The National Cancer Institute (NCI), through NIH Funding Opportunity Announcement PAR-22-165, is offering R21 grant support for early-stage, exploratory research that tackles cancer communication challenges in todays rapidly changing information environment. The focus is on communication science as it relates to cancer prevention and control, meaning projects should connect communication processes and exposures to real behavioral targets and health outcomes, such as screening uptake, vaccination, risk reduction behaviors, treatment decision-making, survivorship behaviors, and related cancer outcomes. The FOA is labeled "Clinical Trial Optional," so applicants may propose studies that include clinical trial elements if appropriate, but a clinical trial is not required.
The opportunity is organized around three main research domains. First, NCI is looking for work on new cancer communication surveillance approaches, especially research that tests the usefulness and practical application of modern methods for tracking and understanding cancer-related communication in the current media ecosystem. This can include studying how people encounter, interpret, and share cancer information across digital platforms, social networks, and mixed media environments, and how those information patterns can be measured reliably and efficiently for public health and research purposes. Second, the FOA encourages the development and testing of rapid pilot communication interventions. These are smaller, quicker studies that use innovative methods and study designs to prototype, refine, and get early evidence on communication strategies meant to improve cancer-related behaviors or outcomes. Third, NCI highlights the need for multilevel cancer communication models that explicitly consider two-way, bidirectional influence across levels, such as how individual beliefs and behaviors interact with family dynamics, clinical teams, community contexts, organizations, media systems, and policy environments, and how influences travel in both directions rather than only top-down.
Across all three domains, applications are expected to use one or more innovative communication research methodologies. In practice, that means applicants should go beyond conventional survey-only approaches when appropriate and consider methods that better match the new information ecosystem, such as designs that capture dynamic information flows, real-time exposure, network effects, platform-specific communication, or rapidly shifting narratives. The overarching expectation is that projects will advance how cancer communication is measured, modeled, or intervened upon, with clear relevance to prevention and control.
Eligibility is broad and includes many types of domestic U.S. organizations and governments. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly notes additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
At the same time, the FOA places firm limits on foreign involvement. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible to apply, and foreign components as defined by NIH policy are not allowed. In other words, the applicant organization and the work proposed under the grant need to remain within the allowable domestic scope.
This is a discretionary grant program under NIH, listed under CFDA 93.399, with an original closing date shown as 2025-09-07. The announcement does not provide an award ceiling or expected number of awards in the provided text, so applicants would need to consult the full FOA and NIH guidance for budget structure typical of the R21 mechanism. Overall, the opportunity is designed for creative, high-impact pilot and methods-driven studies that help NCI and the broader field understand and improve cancer communication in a media landscape shaped by digital platforms, rapid information spread, and complex multilevel influences.Apply for PAR 22 165
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399.
- This funding opportunity was created on 2022-06-13.
- Applicants must submit their applications by 2025-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional)
Previous opportunity: Bilateral Water Activity
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 165
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 165) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) Apply for PAR 22 164 Funding Number: PAR 22 164 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional) Apply for PAR 22 198 Funding Number: PAR 22 198 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 026 Funding Number: RFA CA 22 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: $5,500,000 |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional) Apply for PAR 22 199 Funding Number: PAR 22 199 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed) Apply for RFA DA 23 052 Funding Number: RFA DA 23 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional) Apply for RFA DA 23 011 Funding Number: RFA DA 23 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) Apply for PAR 22 173 Funding Number: PAR 22 173 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) Apply for PAR 22 174 Funding Number: PAR 22 174 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed) Apply for RFA DA 23 017 Funding Number: RFA DA 23 017 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| NIDA Program Project Grant Applications (P01 Clinical Trial Optional) Apply for PAR 22 201 Funding Number: PAR 22 201 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only) Apply for RFA DA 23 018 Funding Number: RFA DA 23 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional) Apply for RFA DA 23 046 Funding Number: RFA DA 23 046 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed) Apply for RFA DA 23 045 Funding Number: RFA DA 23 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed) Apply for RFA NS 23 014 Funding Number: RFA NS 23 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Point-of-Care Technologies Research Network: Technology Research and Development Centers (TRDC) (U54 Clinical Trial Optional) Apply for PAR 22 203 Funding Number: PAR 22 203 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,200,000 |
| HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional) Apply for RFA DA 23 051 Funding Number: RFA DA 23 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional) Apply for RFA AT 23 001 Funding Number: RFA AT 23 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) Apply for RFA AT 23 002 Funding Number: RFA AT 23 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required) Apply for PAS 22 207 Funding Number: PAS 22 207 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) Apply for PAR 22 216 Funding Number: PAR 22 216 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 165", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
